SA PRO
Free Account
Themes
Bristol-Myers Squibb CompanyBMYNYSE
Loading
OverviewIntelligenceChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
30 analysts·High coverage
43%
Rating Distribution
Strong Buy
00%
Buy
1343%
Hold
1550%
Sell
27%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Current price is 0% above analyst consensus — near fair value expected.

Bear Case
$40.00
-36%
Consensus
$62.27
-0%
Bull Case
$75.00
+20%
Price Range30 analysts
Low
Consensus
High
$40.00
$75.00
Current Target
Current Price
$62.34
Above Target
$0.07

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Feb 24, 2026RBC Capital
RBC Capital Starts Bristol-Myers Squibb Co. (BMY) at Sector Perform
Target:$60.00
-2.6%from $61.60
Feb 23, 2026Piper Sandler
Bristol Myers price target raised to $75 from $66 at Piper Sandler
Target:$75.00
+23.6%from $60.66
Feb 19, 2026Barclays
Bristol Myers initiated with an Overweight at Barclays
Target:$75.00
+24.4%from $60.30
Feb 6, 2026Morgan Stanley
Bristol Myers price target raised to $40 from $37 at Morgan Stanley
Target:$40.00
-35.3%from $61.86
Feb 6, 2026Guggenheim
Bristol Myers price target raised to $72 from $62 at Guggenheim
Target:$72.00
+21.0%from $59.52
Feb 6, 2026Wells Fargo
Bristol Myers price target raised to $60 from $55 at Wells Fargo
Target:$60.00
+0.8%from $59.52
Jan 28, 2026Piper Sandler
Bristol Myers price target raised to $66 from $62 at Piper Sandler
Target:$66.00
+18.8%from $55.56
Jan 13, 2026Leerink Partners
Bristol Myers price target raised to $60 from $54 at Leerink
Target:$60.00
+6.4%from $56.39
Jan 9, 2026Scotiabank
Bristol Myers price target raised to $60 from $53 at Scotiabank
Target:$60.00
+7.4%from $55.87
Jan 7, 2026UBS
Bristol Myers upgraded to Buy from Neutral at UBS
Target:$65.00
+15.2%from $56.41
Dec 12, 2025Morgan Stanley
Bristol Myers price target raised to $37 from $36 at Morgan Stanley
Target:$37.00
-29.7%from $52.63
Dec 12, 2025Guggenheim
Bristol Myers upgraded to Buy from Neutral at Guggenheim
Target:$62.00
+21.1%from $51.20
Dec 10, 2025HSBC
Bristol Myers price target raised to $53 from $50 at HSBC
Target:$53.00
+4.6%from $50.68
Dec 4, 2025Scotiabank
Bristol-Myers Squibb Co. (BMY) PT Raised to $53 at Scotiabank
Target:$53.00
+4.0%from $50.96
Dec 3, 2025Truist Financial
Truist Securities on Bristol-Myers Squibb Co. (BMY): 'overall positive'
Target:$65.00
+27.5%from $50.98
Aug 5, 2025Daiwa
Bristol Myers downgraded to Neutral from Outperform at Daiwa
Target:$42.00
-8.4%from $45.85
Jul 21, 2025Truist Financial
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Target:$84.00
+78.3%from $47.12
Apr 23, 2025Jefferies
Bristol Myers price target lowered to $68 from $70 at Jefferies
Target:$68.00
+40.1%from $48.52
Apr 22, 2025Piper Sandler
Piper Sandler bullish on Bristol Myers, initiates with an Overweight
Target:$65.00
+30.5%from $49.82
Nov 12, 2024BMO Capital
Bristol Myers price target raised to $61 from $57 at BMO Capital
Target:$61.00
+8.5%from $56.23
Nov 1, 2024BMO Capital
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at BMO Capital
Target:$57.00
+4.9%from $54.32
Sep 23, 2024BMO Capital
BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
Target:$48.00
-3.1%from $49.56
Jul 29, 2024Goldman Sachs
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at Goldman Sachs
Target:$57.00
+12.8%from $50.55
Jul 29, 2024Barclays
Bristol Myers downgraded to Underweight from Equal Weight at Barclays
Target:$41.00
-18.7%from $50.45
Jul 12, 2024UBS
Bristol Myers price target lowered to $43 from $47 at UBS
Target:$43.00
+5.7%from $40.68

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance